Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Study Status: 
Study Description: 

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.


We are looking for participants who:

-- do not have memory problem

-- are between age 65 and 85

-- have a reliable caregiver or family member who knows them well

-- are in stable medical condition

-- are willing to undergo MRI and PET scans


More information about the national study may be found at

Check out the study's video at:

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A4 Web Blurb.pdf82.07 KB